Eli Lilly will buy privately held SiteOne Therapeutics in a deal worth as much as $1 billion, the companies said on Tuesday, ...

Eli Lilly and Company (India) partners with Apollo Group to enhance awareness and healthcare solutions for obesity and type 2 ...

Viking Therapeutics faces tough obesity drug rivals, with VK2735 showing promise but an uncertain edge. Find out why VKTX ...

The collaboration will span over 200 Apollo clinics and involve 300 medical practitioners, focusing on patient education, ...

Novo Nordisk’s weight-loss drug Wegovy has been surpassed in weekly U.S. prescriptions by Eli Lilly’s Zepbound, and now the ...

Eli Lilly's growth is impressive, but its current valuation is only justifiable with sustained high growth. Click here to ...

The initiative is planned to roll out across more than 200 Apollo clinics and involve 300 medical practitioners ...

We recently published a list of Did Jim Cramer Nail or Miss These 11 Stock Predictions? In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other ...

Eli Lilly and Company (India) on Thursday said it has inked a pact with Apollo Group to raise awareness about obesity and type 2 diabetes. The company has ...

Lilly dominates GLP-1 market but faces near-term headwinds, while AstraZeneca boasts steady growth, rising estimates and a higher dividend yield.

Zuellig Pharma introduces Eli Lilly’s innovative obesity and diabetes medicine, Mounjaro in Thailand: Bangkok, Thailand Thursday, May 29, 2025, 11:00 Hrs [IST] Zuellig Pharma, a ...

Novo Nordisk was Europe's most valuable company, with a big lead on obesity drugs with its runaway hits Ozempic and Wegovy. Then it smashed into roadblocks - shortages that led Novo to limit demand by ...